PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: MultivalentBiological: Tdap
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT02955160
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT02954653
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson, Tucson, Arizona, United States
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Other: Chemoradiation
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 697
- Registration Number
- NCT02952586
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: AvelumabBiological: UtomilumabBiological: RituximabOther: Azacitidine
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT02951156
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇮🇹Istituto Clinico Humanitas, Rozzano, MI, Italy
🇺🇸City of Hope, Duarte, California, United States
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
- Conditions
- Primary Hyperlipidemia or Mixed Dyslipidemia
- Interventions
- Biological: BococizumabDrug: Placebo
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02947334
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT02936154
- Locations
- 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02929576
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 702
- Registration Number
- NCT02928224
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Investigational Drug Services, Westwood, Kansas, United States
🇧🇷Hospital do Olho, Salvador, Bahia, Brazil
🇦🇹DZU, Diagnose Zentrum Urania GmbH, Wien, Austria
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
- Conditions
- Ankylosing SpondylitisPsoriatic ArthritisUlcerative ColitisRheumatoid ArthritisCrohn Disease
- Interventions
- Other: QOL questionaire
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1431
- Registration Number
- NCT02925338
- Locations
- 🇫🇷
Centre Hospitalier, Metz Tessy, France
🇫🇷Hopital Saint Philibert, Lomme, France
🇫🇷Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre, Strasbourg, Alsace, France
A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Filgrastim HospiraBiological: US-Approved Neupogen
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT02923791
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
🇺🇸Seaview Jacksonville LLC, Jacksonville, Florida, United States